Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10326381" target="_blank" >RIV/00064165:_____/16:10326381 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/16:10326381

Result on the web

<a href="http://dx.doi.org/10.1093/eurheartj/suw009" target="_blank" >http://dx.doi.org/10.1093/eurheartj/suw009</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/eurheartj/suw009" target="_blank" >10.1093/eurheartj/suw009</a>

Result language

angličtina

Original language name

Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia

Original language description

A panel of European experts on lipids and cardiovascular disease discussed clinical approaches to managing cardiovascular risk in clinical practice, including residual cardiovascular risk associated with lipid abnormalities, such as atherogenic dyslipidaemia (AD). A simplified definition of AD was proposed to enhance understanding of this condition, its prevalence, and its impact on cardiovascular risk. Atherogenic dyslipidaemia can be defined by high fasting triglyceride levels (a parts per thousand yen2.3 mmol/L) and low high-density lipoprotein cholesterol (HDL-c) levels (a parts per thousand currency sign1.0 and a parts per thousand currency sign1.3 mmol/L in men and women, respectively) in statin-treated patients at high cardiovascular risk. The use of a single marker for the diagnosis and treatment of AD, such as non-HDL-c, was advocated. Interventions including lifestyle optimization and low-density lipoprotein (LDL)-lowering therapy with statins (+/- ezetimibe) are implemented by all experts. Treatment of residual AD can be performed with the addition of fenofibrate, since it can improve the complete lipoprotein profile and reduce the risk of cardiovascular events in patients with AD. Specific clinical scenarios in which fenofibrate may be prescribed are discussed, and include patients with very high triglycerides (a parts per thousand yen5.6 mmol/L), patients who are intolerant or resistant to statins, and patients with AD and at high cardiovascular risk. The fenofibrate-statin combination was considered by the experts to benefit from a favourable benefit-risk profile. Cardiovascular experts adopt a multifaceted approach to the prevention of atherosclerotic cardiovascular disease, with lifestyle optimization, LDL-lowering therapy, and treatment of AD with fenofibrate routinely used to help reduce a patient's overall cardiovascular risk.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FA - Cardiovascular diseases including cardio-surgery

OECD FORD branch

—

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European Heart Journal, Supplement

ISSN

1520-765X

e-ISSN

—

Volume of the periodical

18

Issue of the periodical within the volume

C

Country of publishing house

GB - UNITED KINGDOM

Number of pages

11

Pages from-to

"C2"-"C12"

UT code for WoS article

000374478200002

EID of the result in the Scopus database

2-s2.0-84983080833